eli lilly retatrutide study Lilly's triple agonist hits 28.3% mean weight loss in TRIUMPH-1 phase 3, blowing past tirzepatide benchmarks & rewriting obesity math for payers, PBMs & the Novo Duopoly Eli Lilly's Retatrutide Shows Groundbreaking

Often the first-line option for patients new to GLP-1 therapy

Contact your GP to discuss concerns confidentially, access specialist NHS addiction services, or contact organisations such as We Are With You, FRANK, or Alcoholics Anonymous

Each pen contains one injection at one dose

Olivares M, Neyrinck AM, Ptgens SA, Beaumont M, Salazar N, Cani PD, Bindels LB, Delzenne NM

The FDA is currently reevaluating its recent decision to remove Eli Lillys obesity and diabetes medications, Zepbound and Mounjaro, from the shortage list, allowing compounding pharmacies to continue producing their versions temporarily

Ma C, Avenell A, Bolland M, Hudson J, Stewart F, Robertson C, et al